Lead drug being developed by partner Sierra Oncology
Data on SRA737 should be published at a leading cancer conference
It has two other preclinical treatments – one for autoimmune disease the other for cancer
Sareum Holdings PLC's (LON:SAR) most advanced programme was developed in collaboration with the Institute of Cancer Research and the CRT Pioneer Fund. It is undergoing two Phase II clinical trials conducted by licence partner Sierra Oncology. There are a further two trials planned. The drug developer has two other preclinical discoveries - focused on autoimmune disease and cancer.
This is a checkpoint kinase 1 inhibitor, a type of drug that controls a cancer cell's response to DNA damage. Sareum’s NASDAQ-listed partner is currently refining trials of the drug following the emergence of new data. It will focus efforts on a form of ovarian cancer. This “reprioritising and enlarging” of the ongoing Phase I/II studies have meant that the publication of clinical data is now expected to take place in mid-2019. Sierra has suggested read-out will be submitted for presentation at ASCO, America’s largest cancer conference, which takes place at the end of May running into early June.
What else does Sareum have?
Earlier in the pipeline are SDC-1801, for auto-immune diseases, and SDC-1802, for cancer. Preclinical programmes have been mapped out for each discovery with the aim of getting them into the clinic in 2020. Both are members of the Janus Kinase (JAK) family and specifically are TYK2/JAK1 kinases. They work by inhibiting the activity of one or more of the Janus kinase family of enzymes.
What the broker says
Hybridan reckons Sareum is “arguably a bargain target for the relatively large group of biotech and pharma companies interested in TYK2 and the wider JAK inhibitor space.”